Coronavirus company news summary – Valneva signs deal to deliver 60m Covid-19 vaccine doses to EU - Oncotelic reports positive top-line data from OT-101 Covid-19 study
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

Coronavirus company news summary – Valneva signs deal to deliver 60m Covid-19 vaccine doses to EU – Oncotelic reports positive top-line data from OT-101 Covid-19 study

24 Nov 2021

Valneva has signed an Advance Purchase Agreement (APA) with the European Commission for its inactivated Covid-19 vaccine candidate called VLA2001. Under the APA, Valneva will deliver up to 60 million doses of VLA2001 over two years. The company plans to supply 24.3 million doses during the second and third quarters of next year, however the delivery is subject to approval of VLA2001 by the European Medicines Agency.

Oncotelic Therapeutics has reported positive top-line data from an ongoing study that assessed the safety and efficacy of OT-101 against Covid-19. OT-101 is an anti-TGF-β ribonucleic acid (RNA) therapeutic that demonstrated single agent activity in relapsed/refractory cancer patients. Currently, the therapeutic is being investigated against hospitalised severe Covid-19 patients in Oncotelic’s C001 clinical trial. According to the top-line data, mortality rate at the end of treatment for the entire study population stood at 4.5% for OT-101, compared to 20% for placebo.

Swiss drugs regulator Swissmedic has authorised the use of Pfizer-BioNTech‘s Covid-19 boosters for all individuals aged 16 years and over. The move further expands booster vaccination amid increasing Covid-19 cases in the country. Swissmedic decided to expand the usage after assessing a study with 10,000 participants, among other factors. According to a statement, the booster dose will be administered at least six months after the second shot.